Your browser is no longer supported. Please, upgrade your browser.
Settings
AYTU Aytu BioScience, Inc. daily Stock Chart
AYTU [NASD]
Aytu BioScience, Inc.
Index- P/E- EPS (ttm)-1.88 Insider Own2.90% Shs Outstand19.65M Perf Week-0.40%
Market Cap14.80M Forward P/E- EPS next Y-0.14 Insider Trans- Shs Float18.59M Perf Month-8.17%
Income-24.20M PEG- EPS next Q-0.26 Inst Own40.80% Short Float4.08% Perf Quarter-1.53%
Sales8.70M P/S1.70 EPS this Y77.30% Inst Trans50.89% Short Ratio4.50 Perf Half Y-46.60%
Book/sh0.97 P/B0.78 EPS next Y84.90% ROA-54.10% Target Price4.88 Perf Year-31.55%
Cash/sh0.27 P/C2.79 EPS next 5Y- ROE-227.30% 52W Range0.65 - 2.61 Perf YTD-22.57%
Dividend- P/FCF- EPS past 5Y65.20% ROI- 52W High-71.15% Beta4.60
Dividend %- Quick Ratio1.00 Sales past 5Y492.80% Gross Margin74.20% 52W Low15.85% ATR0.07
Employees53 Current Ratio1.10 Sales Q/Q77.80% Oper. Margin- RSI (14)48.00 Volatility14.12% 8.99%
OptionableNo Debt/Eq0.00 EPS Q/Q98.30% Profit Margin- Rel Volume8.02 Prev Close0.71
ShortableYes LT Debt/Eq0.00 EarningsFeb 20 Payout- Avg Volume168.54K Price0.75
Recom1.50 SMA20-0.18% SMA50-8.26% SMA200-41.21% Volume1,351,176 Change5.55%
Feb-19-20 12:00PM  All You Need to Know About Aytu Bioscience, Inc. (AYTU) Rating Upgrade to Buy Zacks -8.19%
Feb-18-20 09:00AM  Aytu BioScience Completes Acquisition of Innovus Pharmaceuticals ACCESSWIRE
Feb-13-20 04:10PM  Aytu Reports Q2 Revenue of $3.2M, Up 77% Year-over-Year and 121% Sequentially ACCESSWIRE
Feb-06-20 09:00AM  Aytu BioScience to Report Fiscal Q2 FY 2020 Results and Business Update ACCESSWIRE
Feb-05-20 09:00AM  Aytu BioScience Announces Acceptance of Results of Two Natesto Clinical Studies for Presentation at American Urological Association Annual Scientific Program ACCESSWIRE
Jan-30-20 12:31PM  Aytu Bioscience, Inc. (AYTU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jan-28-20 09:00AM  Aytu BioScience Announces Acceptance of Natesto Spermatogenesis Study Results for Presentation at ENDO 2020 ACCESSWIRE
Jan-27-20 09:00AM  Aytu BioScience and Innovus Pharmaceuticals Announce Effectiveness of Form S-4 Registration Statement Related to Proposed Acquisition of Innovus by Aytu BioScience ACCESSWIRE
Dec-24-19 08:05AM  Aytu BioScience and Innovus Pharmaceuticals Announce Filing of Form S-4 Registration Statement Related to Proposed Acquisition of Innovus by Aytu BioScience ACCESSWIRE +13.66%
Dec-21-19 03:43PM  Hedge Funds Are Warming Up To Aytu BioScience, Inc. (AYTU) Insider Monkey
Dec-17-19 11:30PM  Rigrodsky & Long, P.A. Files Class Action Suit Against Aytu BioScience, Inc. GlobeNewswire
Dec-14-19 09:12AM  INVESTOR ALERT: Monteverde & Associates PC Is Investigating The Following Transaction ACCESSWIRE
Dec-13-19 09:50AM  CERC: Expansion in Rare and Orphan Diseases with Acquisition of Aevi Genomic Medicine Zacks Small Cap Research +10.57%
Dec-12-19 01:19PM  SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of the Following Mergers GlobeNewswire +19.48%
09:13AM  SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation Regarding the November 21, 2019 Preliminary Proxy Statement of AYTU BIOSCIENCE, INC. - AYTU PR Newswire
Dec-05-19 09:42PM  Edited Transcript of AYTU earnings conference call or presentation 14-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
06:05AM  MiOXSYS Male Infertility Test Will be Featured in Product Symposium at the 8th Annual Congress of the German Federation of Reproductive Biology and Medicine ACCESSWIRE
Dec-03-19 08:05AM  Aytu BioScience to Present at LD Micro 12th Annual Main Event Investor Conference on December 11, 2019 ACCESSWIRE
Dec-02-19 08:05AM  Aytu BioScience Announces Launch of Natesto(R) U.S. Co-Promotion with Acerus Pharmaceuticals ACCESSWIRE
Nov-19-19 08:00AM  Aytu BioScience Announces Addition of Tuzistra(R) XR to Leading Pharmacy Benefit Managers National Formulary ACCESSWIRE
Nov-14-19 07:05PM  Aytu Bioscience, Inc. (AYTU) Reports Q1 Loss, Lags Revenue Estimates Zacks -7.55%
04:01PM  Aytu Reports First Quarter 2020 Financial Results ACCESSWIRE
Nov-11-19 06:05AM  Aytu BioScience Announces Hiring of Matthew Phillips as Executive Vice President of Commercial Operations ACCESSWIRE
Nov-07-19 08:05AM  Aytu BioScience to Report Fiscal Q1 FY 2020 Results and Business Update ACCESSWIRE -6.73%
Nov-04-19 02:15PM  Kaskela Law LLC Announces Stockholder Investigation of Aytu BioScience, Inc. AYTU GlobeNewswire
09:00AM  Aytu BioScience Announces Closing of $12.4M Prescription Product Portfolio Purchase ACCESSWIRE
Nov-01-19 04:35PM  Form D Friday: Greenwood Village-based securities firm raising $50M for real estate fund American City Business Journals
Oct-21-19 07:01AM  Aytu BioScience Announces Addition of Tuzistra(R) XR to Leading National Pharmacy Benefit Manager's Formulary ACCESSWIRE -5.04%
Oct-17-19 08:30AM  Aytu BioScience Announces Positive Clinical Results from Natesto(R) Spermatogenesis Study ACCESSWIRE -8.89%
Oct-16-19 08:30AM  Aytu BioScience to Announce Results from Natesto(R) Spermatogenesis Study on Thursday, October 17 ACCESSWIRE +10.66%
Oct-14-19 06:30AM  Aytu BioScience Acquires $12.4 Million Prescription Product Portfolio ACCESSWIRE
06:15AM  Aytu BioScience Announces $10 Million Private Placement ACCESSWIRE
Oct-02-19 08:05AM  Aytu BioScience and Validus Pharmaceuticals Announce ZolpiMist Co-Promotion Agreement and Launch Into the $163 Million Psychiatry Market ACCESSWIRE
Sep-26-19 04:02PM  Aytu BioScience Reports 100% Revenue Growth to $7.3 million in FY 2019 ACCESSWIRE
Sep-24-19 08:05AM  Aytu BioScience Announces Addition of Natesto(R) to Leading National Pharmacy Benefit Managers Formulary; Natesto Added to Commercial Plans Covering Over 30 Million U.S. Lives ACCESSWIRE
Sep-19-19 08:05AM  Aytu BioScience to Report Fiscal FY 2019 Results and Business Update ACCESSWIRE
Sep-17-19 08:05AM  Aytu BioScience to Present at Ladenburg Thalmann 2019 Healthcare Conference ACCESSWIRE
Sep-12-19 08:05AM  Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals ACCESSWIRE
Sep-10-19 08:05AM  Aytu BioScience Announces Availability of the MiOXSYS(R) Male Infertility Test in South Africa ACCESSWIRE +5.26%
Sep-05-19 11:31AM  Do Insiders Own Lots Of Shares In Aytu BioScience, Inc. (NASDAQ:AYTU)? Simply Wall St.
Sep-04-19 08:05AM  Aytu BioScience Announces Tuzistra XR Co-Promotion Agreement with Poly Pharmaceuticals ACCESSWIRE
Aug-16-19 11:23AM  What's in Store for Aytu BioScience's (AYTU) Q4 Earnings? Zacks
Aug-05-19 08:05AM  Aytu BioScience Announces First ZolpiMist(TM) Clinical Study Results Demonstrating More Rapid Sleep Onset with Lingual Spray Zolpidem versus Oral Tablet ACCESSWIRE
Aug-01-19 09:30AM  Is Aytu Bioscience (AYTU) Outperforming Other Medical Stocks This Year? Zacks
08:05AM  Natesto Spermatogenesis Study Final Results Accepted for Presentation at 'Late-Breaking' Session at the American Society for Reproductive Medicine 75th Annual Scientific Conference ACCESSWIRE
Jul-30-19 07:00AM  Aytu BioScience Expands Natesto(R) Partnership with Acerus Pharmaceuticals to Accelerate Natesto Growth in the U.S. ACCESSWIRE
07:00AM  Acerus And Aytu Bioscience To Co-Promote NATESTO® In The United States PR Newswire
Jul-24-19 08:05AM  Natesto(R) Added to National Pharmacy Benefit Manager's Formulary Natesto Now Covered on Payer Plans Covering Over 6 Million U.S. Lives ACCESSWIRE
Jul-08-19 10:24AM  The Zacks Analyst Blog Highlights: Middlesex Water, Howard Hughes, Ubiquiti, Aptose and Aytu Zacks +5.41%
09:55AM  Sarepta Stock Up Almost 40% This Year So Far: Here's Why Zacks
08:47AM  Aytu BioScience Shares Clinical Results For Natesto Testosterone Medication Benzinga
06:05AM  Aytu BioScience Announces Publication of Clinical Study Results Demonstrating Effectiveness of Natesto(R) Regardless of Patients Baseline Hypogonadism Severity ACCESSWIRE
Jul-05-19 08:38AM  Bond Yields Plunge Globally on Slowdown Fears: 5 Safe Picks Zacks
Jul-01-19 08:05AM  Aytu BioScience Added to Russell Microcap(R) Index ACCESSWIRE
Jun-25-19 08:05AM  Aytu BioScience Announces First Clinical Results Demonstrating Clinical Utility of MiOXSYS Male Infertility Test When Used Prior to In Vitro Fertilization (IVF) Procedures ACCESSWIRE
Jun-24-19 04:00AM  MiOXSYS(R) Male Infertility Test Will be Featured in Product Theatre Symposium at 35th Annual Meeting of the European Society of Human Reproduction and Embryology ACCESSWIRE
Jun-18-19 08:05AM  Aytu BioScience Announces Presentation of Novel Clinical Findings for its Proprietary MiOXSYS(R) Male Infertility Test at Global Reproductive Medicine Scientific Conference ACCESSWIRE
Jun-12-19 08:05AM  Aytu BioScience Featured in Local NBC News Segment (VIDEO): ''Nasal Spray for Low Testosterone Preserves Fertility'' ACCESSWIRE
Jun-11-19 08:05AM  Aytu BioScience Set to Join Russell Microcap (R) Index ACCESSWIRE
Jun-05-19 09:02AM  Myriad Genetics Announces Study Results Of myRisk Cancer Test Zacks
Jun-04-19 08:05AM  Aytu BioScience Announces Exclusive Distribution Agreement with Beijing Dahua Sanxin Technology Development Co., Ltd. to Commercialize MiOXSYS(R) Male Infertility Test in China ACCESSWIRE +15.13%
May-30-19 09:30AM  Is Aytu Bioscience (AYTU) Outperforming Other Medical Stocks This Year? Zacks
May-21-19 08:05AM  Aytu BioScience Announces Availability of the MiOXSYS(R) Male Infertility Test in the United Kingdom ACCESSWIRE +6.11%
May-17-19 09:00AM  All You Need to Know About Aytu Bioscience, Inc. (AYTU) Rating Upgrade to Strong Buy Zacks
May-14-19 08:01AM  Aytu BioScience Reports 291% Revenue Growth in Q3 FY19 ACCESSWIRE
May-07-19 08:05AM  Aytu BioScience to Report Fiscal Third Quarter 2019 Results and Business Update ACCESSWIRE
Apr-24-19 08:05AM  Aytu BioScience Announces Submission of ZolpiMist (TM) for Approval to Australian Therapeutic Goods Administration (TGA) ACCESSWIRE
Apr-16-19 08:05AM  Aytu BioScience Appoints Steven Boyd to the Company's Board of Directors ACCESSWIRE
Apr-11-19 09:00AM  Aytu Bioscience, Inc. (AYTU) Moves to Buy: Rationale Behind the Upgrade Zacks
Mar-27-19 08:05AM  Aytu BioScience Provides Study Update for Spermatogenesis Study of Natesto (R), the Only FDA-Approved, Nasally-Administered Testosterone Treatment ACCESSWIRE
Mar-19-19 08:05AM  Aytu BioScience Announces Two Recent Publications Highlighting Improved Efficacy and Patient Preference of Natesto Nasal Testosterone over Topical Gels ACCESSWIRE +18.60%
Mar-14-19 08:05AM  Aytu BioScience Announces Natesto(R) Presentations at Two Upcoming Scientific Conferences ACCESSWIRE
Mar-11-19 10:40AM  Aytu Bioscience, Inc. (AYTU) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Mar-09-19 08:39AM  What Percentage Of Aytu BioScience, Inc. (NASDAQ:AYTU) Shares Do Insiders Own? Simply Wall St.
Mar-07-19 12:00AM  Aytu BioScience Announces ZolpiMist (TM) Global Distribution Agreement with SUDA Pharmaceuticals ACCESSWIRE
Mar-06-19 08:05AM  Aytu BioScience Announces ZolpiMist(TM) Global Distribution Agreement with SUDA Pharmaceuticals ACCESSWIRE +29.09%
Feb-07-19 08:31AM  Aytu BioScience Reports 71% Revenue Growth in Q2 FY19 ACCESSWIRE -18.94%
Jan-31-19 08:05AM  Aytu BioScience to Report Fiscal Second Quarter 2019 Results and Business Update ACCESSWIRE
Jan-15-19 08:05AM  Aytu BioScience Announces U.S. Field Sales Launch of Tuzistra(R) XR ACCESSWIRE +14.95%
Jan-10-19 07:05AM  Aytu BioScience Provides Natesto(R) Commercial Update for the Quarter Ending December 31, 2018, Reports 27% Prescription Growth and Expansion of Natesto(R) Direct Program ACCESSWIRE +5.31%
Dec-06-18 07:05AM  Aytu BioScience Announces Commercial Availability of Tuzistra(R) XR (codeine polistirex and chlorpheniramine polistirex) oral suspension ACCESSWIRE
Dec-04-18 07:05AM  Aytu BioScience Provides Webcast Information for 2018 LD Micro Conference Presentation ACCESSWIRE
Dec-03-18 07:05AM  Aytu BioScience Announces Appointment of Two New Directors, Steven Boyd and Ketan Mehta ACCESSWIRE
Nov-30-18 07:05AM  Aytu BioScience Announces Closing of $5M Investment from Armistice Capital ACCESSWIRE +14.81%
Nov-16-18 08:50AM  Investor Expectations to Drive Momentum within ANGI Homeservices, Aytu Bioscience, IRIDEX, Cellular Biomedicine Group, CounterPath, and EXFO Discovering Underlying Factors of Influence GlobeNewswire -5.01%
Nov-15-18 07:05AM  Aytu BioScience Announces Positive Interim Results from Natesto(R) Spermatogenesis Study ACCESSWIRE -5.65%
Nov-13-18 07:05AM  Aytu BioScience to Report Interim Results from Natesto(R) Spermatogenesis Study on Thursday, November 15, 2018 ACCESSWIRE +14.15%
Nov-07-18 03:01PM  Aytu BioScience Reports 55% Sequential Revenue Growth in Q1 FY19; Adds Tuzistra(R) XR to Portfolio ACCESSWIRE
09:30AM  Biotech Stocks and the Midterm Elections ACCESSWIRE
Nov-05-18 07:05AM  Aytu BioScience Enters $3 Billion Cough and Cold Market and Expands Primary Care Portfolio, with Exclusive U.S. Licensing of Revenue-Generating, FDA-Approved Antitussive Tuzistra(R) XR ACCESSWIRE
Oct-31-18 08:05AM  Aytu BioScience to Report Fiscal First Quarter 2019 Results and Business Update ACCESSWIRE
Oct-11-18 09:35AM  These 16 public Colorado companies are concerned about tariffs, according to recent SEC filings American City Business Journals
08:05AM  Aytu BioScience Announces Issuance of First U.S. Patent Covering MiOXSYS(R) for Male Infertility; Company Progresses Toward U.S. Regulatory Clearance and Commercialization ACCESSWIRE
Oct-10-18 08:05AM  Aytu BioScience Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option ACCESSWIRE
Oct-05-18 10:01AM  Aytu, KemPharm stocks plunge to pace Nasdaq decliners after share offerings MarketWatch -36.14%
08:30AM  Aytu BioScience Announces Pricing of $13.2 Million Underwritten Public Offering ACCESSWIRE
Oct-01-18 08:00AM  Todays Research Reports on Stocks to Watch: Aytu Bioscience and Altimmune ACCESSWIRE
Sep-21-18 08:00AM  Todays Research Reports on Stocks to Watch: Corbus Pharmaceuticals and Aytu Bioscience ACCESSWIRE -17.65%
Sep-17-18 08:05AM  Aytu BioScience Announces Publication of Manuscript Summarizing Results from the Ongoing Natesto(R) Spermatogenesis Study ACCESSWIRE -6.35%
Sep-06-18 04:03PM  Natesto(R) Q4 Revenue Increases 178% Sequentially; Q4 Product Revenue Increases 52% Sequentially ACCESSWIRE
Aytu BioScience, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. Aytu BioScience, Inc. is based in Englewood, Colorado.